T here is increasing evidence that inflammation plays a central role in the cascade of events that result in plaque erosion and fissuring. 1 Lesional macrophages synthesize matrix metalloproteinases (MMPs), proteolytic enzymes capable of degrading plaque constituents. 2 In particular, 92 kDa gelatinase (MMP-9), which is specialized in the digestion of collagen fragments, has been critically associated with acute ischemic events in humans. 3, 4 The MMP-9 promoter contains a clearly defined NF-B binding site, and NF-B is therefore one of the transduction pathways that ultimately regulate MMP-9 secretion. 5 Furthermore, it has been shown that secretion of MMP-9 by macrophages in human atherosclerotic plaques occurs through a prostaglandin (PG) E 2 -dependent mechanism. 3 PGE 2 biosynthesis is influenced by changes in cyclooxygenase (COX) and PGE synthase (PGES) expression. 3 Two isoforms of COX and 3 of PGES have been identified, referred to as COX-1 and COX-2 and cytosolic PGES (cPGES) and type 1 and type 2 membrane-bound PGES (mPGES-1 and mPGES-2), respectively. Whereas COX-1 and cPGES are constitutively expressed, COX-2 and mPGES-1 are coregulated in nucleated cells in response to growth factors and cytokines, suggesting that these enzymes are involved in the generation of prostaglandins in inflammatory diseases. 3, 6 Consistent with the hypothesis of COX-2 and mPGES-1 contributing to the clinical instability of plaques, we recently reported enhanced MMP-9 production by macrophages in symptomatic plaques caused by the enhancement in PGE 2 synthesis as a result of the induction of the functionally coupled COX-2/mPGES-1. 3 However, prostaglandins also possess antiinflammatory properties. In fact, circulating PGD synthase (PGDS) has been recently identified as a protective factor in reducing the incidence of restenosis in patients undergoing percutaneous transluminal coronary angioplasty. 7 Furthermore, it has been reported that the PGDS derivative 15-deoxy-⌬ 12,14 -PGJ 2 (15d-PGJ), is a potent inhibitor of NF-B 8 and IK 9 and may also exert several antiinflammatory effects through mechanisms involving peroxisome proliferator activated receptor (PPAR␥) activation. 10 It is important to acknowledge that staining for 15-deoxy-⌬ 12,14 -PGJ 2 has been recently reported in macrophages in human atherosclerotic plaques, together with COX-2 expression. 11 There are 2 distinct isoforms of PGDS. One is the hematopoietic PGDS (H-PGDS); the other is the lipocalin-type PGDS (L-PGDS), whose expression has been recently reported in human atherosclerotic plaques. 12 Worth attention is the fact that proinflammatory stimuli such as tumor necrosis factor alpha (TNF␣) found within atherosclerotic lesions reduced PGD 2 synthesis and increased PGE 2 release, 13 whereas glucocorticoids may have opposing effects. 14 Thus, the relative abundance of a specific prostanoid is the result of the expression and activity of its specific isomerase, and the predominant expression of mPGES-1 over L-PGDS might lead to increased inflammation and plaque disruption (Figure 1 ).
This evidence prompted us to investigate whether a shift in the isomerase activity, in the sense of a prevalent biosynthesis of PGE 2 , could lead, in turn, to enhanced inflammatory activation and MMP-9 production in macrophages of ruptureprone plaques (Figure 1 ).
Methods

Patients
Between February and November 2001, we studied 60 of 96 consecutive surgical inpatients enlisted to undergo carotid endarterectomy for high-grade (Ն70%) internal carotid artery stenosis; these patients were not previously included in other clinical studies. Recruitment was completed when 2 predetermined equal groups of 30 patients according to clinical evidence of plaque instability were achieved. The first group included 30 patients who presented with transient ischemic attack or ischemic stroke (symptomatic patients). The second group included 30 patients who had an asymptomatic carotid stenosis (asymptomatic patients). Percentage of stenosis, procedural methods, concomitant therapy, and risk factors did not differ between the 2 groups (Table I , available online at http:// atvb.ahajournals.org). The study was approved by local ethics review committees, and informed written consent was obtained from all patients before each examination.
Reagents
Antibodies anti-human ␣-actin, anti-CD68, anti-CD3, anti-HLA-DR, anti-CD31 (Dako Corporation, Carpenteria, Calif), anti-MMP-9 (Calbiochem-Novabiochem, San Diego, Calif), anti-COX-1, anti-COX-2, anti-L-PGDS, anti-mPGES-1, anti-PPAR␥ (Cayman Chemical, Ann Arbor, Mich), anti-IB␣ (Chemicon, Temecula, Calif), and anti-p65a (Roche Biochemical, Mannheim, Germany), were used.
Immunohistochemistry
Plaque sections were prepared and analyzed as previously described. 3 Analysis of immunohistochemistry was performed with a color image analysis system (AlphaEase 5.02; Alpha Innotech Corp).
Western Blot
Western blot analysis was performed as previously described. 3 Bands were quantified by computer-assisted densitometry (Alpha Ease 5.02) and expressed as densitometric unit (DU).
SDS-PAGE Zymography
Zymographic analysis was performed as previously described. 3 Conditioned medium of human fibrosarcoma cell line HT1080 was used as positive control with known gelatinolytic activity.
Reverse-Transcriptase Polymerase Chain Reaction
Reverse-transcriptase polymerase chain reaction for COX-2 was performed as previously described. 3 The GAPDH gene was amplified as internal control. Results were quantified using computeraided densitometric analysis (Alpha Ease 5.02).
Quantification of NF-B and PPAR␥ Activity
Nuclear extracts from plaque specimens were obtained as described by Ohlsson et al. 15 Subsequently, activated p65 was recognized by selective antibody. 16 In addition, activated p50 and PPAR␥ were measured by specific Trans-AM transcription factor assay kit (Active Motif). 17 
Isolation and Culture of Peripheral Blood Monocytes
The isolation of peripheral monocytes from 5 healthy blood donors was assessed as previously described. 3 Control or stimulated (LPS, 1 g/mL; IL-1␤, 10 ng/mL) monocytes (20ϫ10 6 /4 mL of RPMI) were cultured in the presence of aspirin (200 mol/L) and in the presence or absence of the COX-2 inhibitor NS-398 (1 to 10 mol/L for 30Ј; Cayman), the mPGES-1 inductor TNF␣ (10 ng/mL for 16 hours, Peprotech Inc, Rocky Hill, NJ), 14 and the inhibitor of mPGES-1 activity buthionine-[S, R]-sulfoximine (50 mol/L for 18 hours; Sigma). 18 
Extraction and Culture of Macrophages From Atherosclerotic Plaques
The extraction of macrophages from 5 symptomatic plaques and 5 asymptomatic plaques was assessed as previously described by de Vries et al. 19 In some experiments, isolated cells were cultured in the presence or absence of the COX-1 inhibitor sulindac sulfide (0.1 to 10 mol/L; Cayman) and the COX-2 inhibitor NS-398 (0.1 to 10 mol/L). PGH 2 (0.42 nM; Cayman), PGE 2 (10 Ϫ7 M; Sigma), PGD 2 (10 Ϫ6 M; Cayman), 15d-PGJ 2 (5 mol/L; Cayman), the TXA 2 agonist U46619 (10 Ϫ6 M; Cayman), the PGI 2 analog carbaprostacyclin (10 Ϫ6 M; Cayman), and PGF 2␣ (200 nM; Cayman) were also added to some of the cultures.
Enzyme Immunoassay, Enzyme-Linked Immunosorbent Assay, and Radioimmunoassay Determinations
Plaque content and in vitro release of PGE 2 (from plaque macrophages), PGD 2 (as its stable methyl oximes), and MMP-9 were measured by enzyme immunoassay (Cayman for PGs, Amersham for MMP-9). In vitro release of PGE 2 from blood monocytes was measured by radioimmunoassay. 20 Plaque content and in vitro release of 15d-PGJ 2 was measured by specific enzyme immunoassay (Assay Designs, Inc, Ann Arbor, Mich). In this assay, the crossreactivities for a number of related eicosanoid compounds were determined by dissolving the cross-reactant in the assay buffer at concentrations from 500 000 to 5 pg/mL. These samples were then measured in the 15d-PGJ 2 assay, and the measured 15d-PGJ 2 concentrations at 50% B/Bo were calculated. The percent crossreactivity was calculated by comparison with the actual concentration of cross-reactant in the sample and expressed as percentage. Using this approach, the cross-reactivity with PGD 2 was only 4.92% and, more importantly, that with other non-PGDS-dependent prostaglandins was Ͻ0.01%. Finally, cross-reactivity with arachidonic acid was Ͻ0.03%.
Statistical Analysis
For clinical data and histological examination, variables were compared by use of the 2 test. The significance of difference in enzyme expression and inflammatory cell infiltration between symptomatic and asymptomatic patients was analyzed by Student t test. Data are expressed as percentage or meanϮSD. All calculations were performed using the computer program SPSS 10.0.5.
Results
Inflammatory Cell Infiltration
Plaque area occupied by macrophages and T cells was significantly greater (PϽ0.0001) in symptomatic than in asymptomatic plaques (Table I ). Inflammatory cells in the symptomatic plaques were always characterized by strong expression of HLA-DR antigens, which contrasted markedly with the low expression of HLA-DR in the asymptomatic plaques.
Higher COX-2 Expression in Symptomatic Plaques
COX-2 was more abundant in symptomatic lesions (26Ϯ6% versus 7Ϯ3%, nϭ30, PϽ0.0001) (Figure 2 ). Western blot ( Figure 3 ) and reverse-transcriptase polymerase chain reaction revealed higher COX-2 expression in symptomatic than in asymptomatic plaques (7128Ϯ111 versus 2051Ϯ353 DU for protein expression, nϭ30, PϽ0.0001; 8636Ϯ251 versus 4633Ϯ198 DU for mRNA expression, nϭ30, PϽ0.0001). In contrast, we did not observe any difference regarding COX-1 expression (4213Ϯ85 versus 3987Ϯ64 DU, nϭ30, PϽ0.0001) (Figures 2 and 3 ).
Different Expression of L-PGDS and mPGES-1 in Symptomatic Plaques
Immunohistochemistry revealed strong mPGES-1 immunoreactivity, but only very weak staining for L-PGDS in symptomatic plaques (Figure 2 ). In contrast, L-PGDS was the predominant isomerase in asymptomatic plaques (Figure 2 ). This was particularly evident when serial plaque sections were analyzed for L-PGDS and mPGES-1 (Figure 4a ). Enzyme staining pattern indicates their localization in macrophages and smooth muscle cells. By quantitative image analysis, levels of mPGES-1 in symptomatic plaques significantly exceeded those of L-PGDS (21Ϯ3% versus 5Ϯ2%, nϭ30, PϽ0.0001), whereas the reverse was true in the asymptomatic plaques (4Ϯ2% versus 20Ϯ4%, nϭ30, PϽ0.0001). Furthermore, only weak L-PGDS expression was observed in symptomatic plaques by Western blot, whereas a 7-fold higher signal was demonstrated for mPGES-1 (1052Ϯ110 versus 7022Ϯ322 DU, nϭ30, PϽ0.0001) ( Figure  3) . On the contrary, L-PGDS turned out to be the principal isomerase in asymptomatic plaques (5842Ϯ128 versus 1223Ϯ142 DU, nϭ30, PϽ0.0001) (Figure 3 ). However, a direct and accurate comparison of the levels of L-PGDS and mPGES-1 may be limited by variable antibody affinities. Thus, we confirmed results concerning mPGES-1/L-PGDS expression also by enzyme immunoassay measurements of the plaque content of their metabolites. In fact, PGE 2 was 
Plaque Expression of MMP-9
Staining for MMP-9 was significantly more abundant in the symptomatic than in the asymptomatic lesions (27Ϯ6% versus 7Ϯ2%, nϭ30; PϽ0.0001) (Figure 2 ). Increased MMP-9 in symptomatic plaques was also confirmed by Western blot (6011Ϯ241 versus 3163Ϯ425 DU, nϭ30; PϽ0.0001) (Figure 3 ) and enzyme-linked immunosorbent assay (231Ϯ42 versus 56Ϯ12 ng/mg tissue, nϭ30; PϽ0.0001). Finally, zymography demonstrated that symptomatic plaques contained higher amounts of activated MMP-9 (2736Ϯ312 versus 692Ϯ221 DU, nϭ30; PϽ0.0001).
Reduced Inflammatory Status in Plaques Expressing High L-PGDS
PPAR␥ expression was significantly higher in asymptomatic plaques, with respect to symptomatic plaques, and showed a stable concordance with L-PGDS (6987Ϯ125 versus 2142Ϯ97 DU for protein expression, nϭ30, PϽ0.0001) (Figure 3 ). In particular, higher PPAR␥ expression constantly resulted in enhanced PPAR␥ activity (29Ϯ4 versus 21Ϯ3 pg/g of nuclear extracts, nϭ30; PϽ0.0001). Similarly, IB␣ expression was also significantly higher in asymptomatic plaques (5462Ϯ133 versus 1891Ϯ109 DU, nϭ30, PϽ0.0001) (Figure 3) , showed a strong relationship with L-PGDS, and resulted in NF-B inactivation as reflected by the selective analysis of activated form of p50 (15Ϯ4 versus 23Ϯ5 pg/g of nuclear extracts, nϭ30; PϽ0.0001) and p65 (1261Ϯ142 versus 6411Ϯ231 DU, nϭ30, PϽ0.0001; Figure 3 ).
Colocalization of COX-2, L-PGDS, mPGES-1, and MMP-9 in Macrophages of Symptomatic Plaques
In the first experiment, serial plaque sections were incubated with the primary antibodies anti-CD68, anti-COX-2, anti-L-PGDS, anti-mPGES-1, and anti-MMP-9. Within the lesion, staining always accumulated in the CD68 ϩ macrophages in the plaque shoulder. In the second experiment, immunofluorescence double-labeling with confocal microscopy associated the expression of L-PGDS with COX-2 and mPGES-1 in CD68ϩ cells, both in plaque sections and in plaque-derived macrophages (Figure 4b ).
COX-2 but Not COX-1 Is Implicated in the Generation of PGE 2 and PGD 2
Basal PGE 2 and PGD 2 release was analyzed in plaque-derived macrophages incubated with NS398 and sulindac sulfide. Results shown in Figure 5a clearly suggest that COX-2 but not COX-1 is involved in PGE 2 and PGD 2 synthesis.
MMP-9 Production in Monocytes Is Selectively Controlled by PGE 2 and PGD 2
To determine whether, in addition to PGE 2 and PGD 2 , other COX-derived prostaglandins may influence MMP-9 produc- tion and plaque stability in the setting of COX-2 overexpression, we examined the effect of PGE 2 , PGD 2 , 15d-PGJ 2 , the TXA 2 agonist U46619, the PGI 2 analog carbaprostacyclin, and PGF 2␣ on MMP-9 expression in unstimulated macrophages derived from symptomatic plaques. As depicted in Figure 5b , MMP-9 biosynthesis was induced by PGE 2 , and inhibited by PGD 2 and 15d-PGJ 2 , whereas no effect was observed for the other prostaglandins.
MMP-9 Production in Monocytes Is a Function of Prevalent PGH 2 -Isomerase
To determine whether a net balance in the isomerase activity in the sense of a mPGES-1-oriented metabolism could lead in turn to MMP-9 production and plaque instability in the setting of COX-2 overexpression, we initially examined the effect of selective mPGES-1 and L-PGDS blockade on NF-B state and MMP-9 production in stimulated monocytes in vitro (Figure 5c ). According to previous studies, 21 (Figure 5c ) only in monocytes in which mPGES-1 was induced by LPS and TNF␣, but not in those in which mPGES-1 was inhibited by buthionine-[S, R]-sulfoximine. We then examined the effect of selective COX-2 blockade on NF-B state and MMP-9 generation in the presence of mPGES-1 stimulation or inhibition. Enhanced NF-B (p65 and p50) and MMP-9 expression by LPS was significantly inhibited by NS-398 in monocytes during mPGES-1 stimulation (1116Ϯ77, 1095Ϯ63, and 1143Ϯ46 DU, respectively; PϽ0.0001), and this inhibition was reversed by the addition of PGE 2 (6954Ϯ113, 6747Ϯ152, and 6543Ϯ147 DU, respectively, PϽ0.0001) (Figure 5c ). In contrast, COX-2 inhibition in the presence of mPGES-1 inhibition paradoxically increased NF-B (p65 and p50) activation and MMP-9 generation (1268Ϯ135 versus 6975Ϯ160, 967Ϯ71 versus 6321Ϯ122 DU, and 1165Ϯ176 versus 6647Ϯ128, respectively; PϽ0.0001), an effect that was reversed by the addition of PGD 2 or 15d-PGJ 2 (2831Ϯ74, 2452Ϯ36, and 2598Ϯ68 DU, respectively; PϽ0.05; Figure  5c ). Similar results were also observed when IL-1␤, a proinflammatory cytokine usually generated in atherosclerotic lesions, was used as stimulus (data not shown). Thus, NF-B and MMP-9 activities appear to be critically influenced by the L-PGDS/mPGES-1 balance in inflammatory cells, and COX-2 overexpression per se could be necessary but not sufficient to induce the detrimental biosynthesis of MMP-9 in human atherosclerotic plaques.
Discussion
In the present report, we provide evidence for the critical involvement of mPGES-1-oriented arachidonic acid metabolism in MMP-9 overexpression in human symptomatic atherosclerotic plaques. In particular, the present findings are the first, to the best of our knowledge, to: (1) provide evidence for an important antiinflammatory role of L-PGDS in human atherosclerotic lesions; and (2) relate the prevailing pathway of PGH 2 metabolism to an acute ischemic event often precipitated by rupture of atherosclerotic plaque.
Concomitantly lower expression of L-PGDS and higher expression of COX-2, mPGES-1, and MMP-9 were found in specimens obtained from the "culprit" carotid lesions of patients with recent transient ischemic attack or stroke compared with specimens obtained from asymptomatic patients. Activated macrophages were significantly more abundant in complicated plaques and represented the major source of functionally coupled COX-2/mPGES-1 and MMP-9. In contrast, although PGDS is predominantly expressed in macrophages, 7 the site of inflammatory infiltration in symptomatic plaques was always characterized by low expression of L-PGDS, which contrasted markedly with the high expression of L-PGDS elsewhere in the asymptomatic plaques. Thus, these data suggest the presence of an active inflamma- Figure 5 . COX-2 but not COX-1 is implicated in the generation of PGE 2 and PGD 2 (a). PGE 2 and PGD 2 release in macrophages derived from symptomatic plaques and incubated with the COX-2 inhibitor NS-398 and the COX-1 inhibitor sulindac sulfide. Effect of PGE 2 , PGD 2 , 15d-PGJ 2 , the TXA 2 agonist U46619, the PGI 2 analog carbaprostacyclin, and PGF 2␣ on MMP-9 expression in unstimulated macrophages extracted from symptomatic plaques (b). L-PGDS expression (c) is responsible for the proinflammatory or antiinflammatory role of COX-2. Purified monocytes with mPGES-1 induction or inhibition were cultured in the presence of aspirin and in the presence or absence of NS-398, and then PGH 2 , LPS, PGE 2 , and 15d-PGJ 2 were added to some of the cultures. The cultures were harvested for Western blot analysis. Results are typical of 3 different experiments.
tory reaction with a PGE 2 -dominated eicosanoid profile in symptomatic plaques. In fact, in agreement with the difference in COX-2, L-PGDS/mPGES-1, and MMP-9 staining pattern, the histological milieu of the lesions appears different with regard to cellularity, presence of foam cells, and cholesterol clefts, but not in the degree of vessel stenosis. This suggests that asymptomatic and symptomatic lesions are primarily different with regard to the inflammatory burden, and these differences in plaque behavior are likely to derive from differences in the presence of as yet uncharacterized stimuli for the selective expression of L-PGDS or mPGES-1 capable of influencing plaque stability. Notably, this hypothesis is also supported by the evidence of a PGES-prevalent eicosanoid profile in macrophages extracted from symptomatic plaques.
We have previously reported enhanced COX-2 and mPGES-1 expression in symptomatic atherosclerotic lesions. 3 However, this study did not provide any evidence about the real contribution of the antiinflammatory L-PGDS in the pathophysiology of plaque rupture. In fact, COX-2 is only an intermediate enzyme in the metabolic pathway of arachidonic acid, and the COX bioproduct PGH 2 is further metabolized by other isomerases to various prostanoids (PGE 2 , PGD 2 , PGF 2␣ , PGI 2 , TXA 2 ). Thus, the relative abundance of a specific prostanoid rather than another is the result of the expression and activity of its specific isomerase, and the concordant inflammatory induction of mPGES-1 with COX-2 in macrophages may lead in turn to a shift in arachidonic acid metabolism from the production of PGD 2 to the preferential synthesis of PGE 2 . 14 The existence of this mechanism has been recently demonstrated in rat peritoneal macrophages in vitro 21 but no evidence exist in human in vivo yet. Our results are consistent with the hypothesis that only the concomitant overexpression of COX-2 and mPGES-1 in the presence of low L-PGDS activity may realize the preferential pathway of arachidonate metabolism leading to increased biosynthesis of PGE 2 -dependent MMP-9 in the setting of human atherosclerotic plaque. On the contrary, COX-2 overexpression in the presence of a PGD 2 -dominated eicosanoid profile is associated with enhanced PPAR␥ and IB␣ activity, and reduced NF-B activity. Important to take into consideration is the fact that the L-PGDS bioproduct 15d-PGJ 2 binds to and activates the nuclear receptor PPAR␥. 9 Furthermore, 15d-PGJ 2 is also an inhibitor of the activation of NF-B induced by inflammatory cytokines. These data are potentially important, because target genes of NF-B include MMP-9 4 and COX-2. In support of these evidences, both PGD 2 and 15d-PGJ 2 were able to completely revert the inflammatory status induced by mPGES-1 in monocytes in vitro in our study. Consequently, the effects of L-PGDS products on PPAR␥ and NF-B are consistent with a critical role for this isomerase in plaque stabilization. However, despite the fact that substantial in vitro evidence suggests that 15d-PGJ 2 activates PPAR␥, 9 and is a potent inhibitor of NF-B, 7 our data seem to suggest that PGD 2 rather than 15d-PGJ 2 may be responsible for the antiinflammatory action of L-PGDS in human atherosclerotic plaques. In particular, this view is supported by the observation that the stimulatory effect of 15d-PGJ 2 on PPAR␥ has been observed in vitro at micromolar concentrations, whereas the quantity of 15d-PGJ 2 measured in atherosclerotic plaques in our study was significantly smaller and probably insufficient to influence PPAR␥ and NF-B activity and, perhaps, to produce any antiinflammatory effect. Thus, we believe that alternative pathways such as direct stimulation of DP receptors by PGD 2 and 15d-PGJ 2 in target cells 22 should be considered for explaining the antiinflammatory action of L-PGDS in human atherosclerotic plaques.
The observation that the PG isomerase profile may influence the proinflammatory or antiinflammatory role of COX-2 in atherosclerotic plaques is in agreement with the recent analog demonstration in macrophages in vitro, 23 and with the observation that COX-2 overexpression, when associated with minimal PGE 2 synthesis and high PGD 2 levels, may contribute to the resolution of inflammation. 24 Thus, our results about the antiinflammatory role of COX-2 in human atherosclerotic plaques in the presence of high L-PGDS levels add new data to the recent observations that COX-2 is responsible for increased biosynthesis of the atheroprotective PGI 2 in the setting of atherosclerosis. 25, 26 Furthermore, this study may contribute, at least in part, to explaining the controversial cardiovascular findings in animals and in humans suggesting that COX-2 inhibition may increase the incidence of cardiovascular events, and may have clinical implication for the prolonged use of selective COX-2 inhibitors in patients with coronary artery disease. In fact, COX-2 inhibition in selected patients with an active inflammatory reaction within recently symptomatic (eg, unstable) atherosclerotic plaques may be beneficial. In contrast, prolonged and widespread use of COX-2 inhibitors in unselected patients with coronary artery disease, most of which have stable, asymptomatic plaques with a low-inflammatory profile, may be detrimental and lead to progressive plaque destabilization.
Finally, L-PGDS may also contribute to the stabilization of COX-2 gene expression in human atherosclerotic plaque during persistent inflammatory stimulation. In fact, 15d-PGJ 2 may exert a negative autoregulatory loop on COX-2 gene in macrophages. 21 In contrast, PGE 2 produced by mPGES-1 may amplify COX-2 overexpression in the active inflammatory infiltrate of atherosclerotic lesions by an EP4-mediated positive feedback loop, further contributing to progressive plaque destabilization. 21 In conclusion, this study addresses the missing link between arachidonic acid metabolism and plaque instability by demonstrating the high prevalence of PGE 2 -dominated eicosanoid profile in symptomatic atherosclerotic lesions and providing evidence that the shift between L-PGDS and mPGES-1 in activated plaque macrophages is associated with transient ischemic attack and stroke, possibly through MMP-9 -induced matrix degradation promoting plaque rupture. These findings are potentially important from a fundamental standpoint, because they demonstrate the critical role of the PGDS/PGES balance in the evolution of atherosclerotic lesions. From a practical standpoint, these findings raise the possibility that drugs able to selectively remodulate arachidonate metabolism in the sense that a PGDS-prevalent path-way might provide a novel form of therapy for atherosclerotic plaque stabilization.
